Based on Biosimilars Advisory Service: Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology, Decision Resources is offering an exclusive analyst call entitled Biosimilar Monoclonal Antibodies: What will be the Main Drivers and Constraints of Uptake for Oncologists? This analyst call is open ONLY to subscribers of this module of the Biosimilars Advisory Service.

Recorded live on Tuesday, October 12, 2010


The Physician Perspectives on Biosimilar G-CSFs and MAbs in Oncology module of the Biosimilars Advisory Service offers extensive primary research with U.S., French and German solid-tumor oncologists and hematologist-oncologists to highlight the key expectations that will drive or constrain biosimilar adoption. This analyst call, presented by Decision Resources Analyst Cindy Fung, Ph.D., answers the following questions:

• What are the clinical trial requirements for solid-tumor tumor oncologists and hematologist-oncologists?
• How will adoption of biosimilar MAbs used in oncology vary by country and by brand?
• Are there differences in the way solid-tumor oncologists and hematologist-oncologists view biologics and biosimilars?
• Which brand will be the most affected by biosimilar erosion? 

Contact us to learn how you can purchase this service and access a recored playback of this event.

Click here to view the invite.